Scholarlink

<p>Glioblastoma (GBM) is a highly aggressive and lethal form of brain cancer with limited treatment options, particularly for recurrent cases. Oncolytic virus (OV) therapy is a novel therapeutic strategy for recurrent GBM, leveraging its ability to selectively target and destroy malignant cells while sparing surrounding healthy tissue. Recent clinical trials have indicated that oncolytic virotherapy has an acceptable safety profile and the potential to enhance survival in recurrent GBM. For instance, CAN-3110, a Nestin-promoter-driven herpes simplex virus-1 (HSV-1), demonstrated a median overall survival of 14.9 months in patients with recurrent GBM, with HSV-1 seropositive patients achieving more prolonged survival (14.2 versus 7.8 months in seronegative patients). This review aims to synthesize the current evidence on clinical outcomes in patients with recurrent GBM receiving oncolytic virotherapy, with a specific focus on safety profiles, therapeutic efficacy, and survival outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical outcomes in recurrent glioblastoma with oncolytic virotherapy: a review

  • 期刊论文

  • 发表日期：

    2026年2月14日

查看全文
  • Feng Tang,
  • Zhen-Yuan Liu,
  • Jin-Zhou Yang,
  • Ya-Di Xu,
  • Zhi-Qiang Li

摘要

Glioblastoma (GBM) is a highly aggressive and lethal form of brain cancer with limited treatment options, particularly for recurrent cases. Oncolytic virus (OV) therapy is a novel therapeutic strategy for recurrent GBM, leveraging its ability to selectively target and destroy malignant cells while sparing surrounding healthy tissue. Recent clinical trials have indicated that oncolytic virotherapy has an acceptable safety profile and the potential to enhance survival in recurrent GBM. For instance, CAN-3110, a Nestin-promoter-driven herpes simplex virus-1 (HSV-1), demonstrated a median overall survival of 14.9 months in patients with recurrent GBM, with HSV-1 seropositive patients achieving more prolonged survival (14.2 versus 7.8 months in seronegative patients). This review aims to synthesize the current evidence on clinical outcomes in patients with recurrent GBM receiving oncolytic virotherapy, with a specific focus on safety profiles, therapeutic efficacy, and survival outcomes.